Horizons in world cardiovascular research. Volume 2 /

Mostrar otras versiones (1)
Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Bennington, Eleanor H.
Formato: Electrónico eBook
Idioma:Inglés
Publicado: New York : Nova Biomedical Books, ©2010.
Colección:Horizons in world cardiovascular research series.
Temas:
Cardiovascular system > Diseases.
Cardiovascular Diseases
Appareil cardiovasculaire > Maladies.
MEDICAL > Cardiology.
Cardiovascular system > Diseases
Acceso en línea:Texto completo
Tabla de Contenidos:
  • HORIZONS IN WORLDCARDIOVASCULAR RESEARCH. VOLUME 2
  • HORIZONS IN CARDIOVASCULAR RESEARCH
  • CONTENTS
  • PREFACE
  • BENEFICIAL CLINICAL EFFECTS OF PERHEXILINEIN CARDIAC PATIENTS: MULTIPLE BIOCHEMICALMECHANISMS
  • ABSTRACT
  • CLINICAL APPLICATIONS OF PERHEXILINE
  • Stable and Unstable Angina Pectoris
  • Aortic Stenosis
  • Heart Failure
  • PHARMACOKINETICS AND TOXICITY OF PERHEXILINE
  • PHARMACOLOGY OF PERHEXILINE
  • Hemodynamics
  • Ion Channels
  • Metabolic Shift
  • Interactions with NO Signaling Pathway
  • NO resistance in cardiovascular disease states
  • Mechanisms of NO resistanceAmelioration of platelet NO resistance by perhexiline
  • Oxidative Stress and Inflammation
  • CONCLUSION AND FUTURE PERSPECTIVES
  • REFERENCES
  • DRUG-INDUCED VALVULAR HEART DISEASE
  • ABSTRACT
  • 1. INTRODUCTION
  • 2. PATHOPHYSIOLOGY OF DRUG-INDUCED VALVULAR HEARTDISEASE
  • 2.1. Serotonin Metabolism
  • 2.2. The Serotonin Transporter (SERT)
  • 2.3. Role of the 5-HT2B Receptor in Drug-Induced Valvular Heart Disease
  • 3. MORPHOLOGICAL AND ECHOCARDIOGRAPHIC CHARACTERISTICS
  • 3.1. Histopathological Features
  • 3.2. Echocardiographical Characteristics4. DRUGS ASSOCIATED WITH VALVULAR HEART DISEASE
  • 4.1. Ergotamine and Methysergide
  • 4.2. Fenfluramine/Phentermine and Dexfenfluramine
  • 4.3. Pergolide and Cabergoline
  • 4.4. Bromocriptine
  • 4.5. 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasyâ€?)
  • 4.6. Other Drugs
  • 5. INFLUENCE OF DRUG DOSE, TREATMENT DURATIONAND RISK FACTORS
  • 6. NATURAL COURSE OF TOXIC VALVULOPATHY
  • 7. SMALL ANIMAL MODELS OF DRUG-INDUCEDVALVULAR HEART DISEASE
  • 8. PRACTICAL RECOMMENDATIONS FOR THE USE OF POTENTIALVALVULOPATHIC DRUGS
  • ABBREVIATIONSREFERENCES
  • SHARED SUSCEPTIBILITY GENES OF METABOLICSYNDROME AND CARDIOVASCULAR DISEASE
  • ABSTRACT
  • INTRODUCTION
  • The Renin Angiotensin System
  • Trigylecrid Metabolism Affecting Genetic Variants
  • Genetic Factors in Glucose Homeostasis
  • Mutations Involved in Inflammatory Pathways
  • Other Contributing Genetic Factors
  • CONCLUDING REMARKS
  • REFERENCES
  • CARDIAC PACING: A REVIEW CHAPTER
  • ABSTRACT
  • INTRODUCTION
  • ELECTRICAL CONDUCTION
  • Blood Pressure
  • Cardiac Output
  • Stroke Volume
  • CLINICAL CARDIAC PACING INDICATIONSAtrioventricular (AV) Block
  • Sinus Node Abnormalities
  • INTRAVENTRICULAR CONDUCTION
  • Cardiac Pacing Therapies
  • Transcutaneous Pacing
  • Temporary Transvenous Pacing
  • Permanent Transvenous Pacing
  • OVERVIEW OF PACEMAKERS
  • Single Chamber Pacing Operation
  • TRANSESOPHAGEAL PACING AND MECHANICAL CARDIAC PACING
  • Transesophageal Pacing
  • Mechanical Cardiac Pacing
  • Pharmacological Remedies
  • FOLLOW-UP
  • SUMMARY
  • REFERENCES

Ejemplares similares